Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript

Nov 6, 2025 / 01:30 PM GMT

Release Date Price: $0.4741 (-11.91%)

Transcript 10-Q8-K

Key Points

Positve

Sangamo Therapeutics Inc (SGMO) presented promising clinical data for ST 920, showing potential as a one-time durable treatment for Fabry disease.
The FDA reaffirmed the use of EGFR slope as an endpoint for accelerated approval, providing a clear regulatory pathway.
The company has initiated patient enrollment in its first neurology clinical study for chronic neuropathic pain, indicating pipeline expansion.
Sangamo Therapeutics Inc (SGMO) received $6 million from Pfizer, enhancing its financial position.
The company is actively pursuing business development opportunities to secure a commercialization partner for its Fabry disease program.

Negative

Sangamo Therapeutics Inc (SGMO) faces ongoing challenges in securing long-term funding to support its operations.
The company is reliant on successful business development discussions to extend its cash runway beyond the first quarter of 2026.
There is uncertainty regarding the outcome of partnership negotiations, which are crucial for the commercialization of its Fabry disease program.
The regulatory process for the Fabry disease drug program remains complex, with ongoing interactions needed with the FDA.
The company must manage the risks associated with its novel gene therapy approaches, including manufacturing and clinical trial execution.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SGMO.OQ - Sangamo Therapeutics Inc
Q3 2025 Sangamo Therapeutics Inc Earnings Call
Nov 06, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Sangamo Therapeutics 3rd quarter 2025 conference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, head of investor relations and corporate communications. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Good morning, everyone.

Thank you for joining us on the call today. On this call are several members of the Sangama executive Leadership team, including Sandy McCraye, Chief Executive Officer, Natalie

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.